NEWS
-
PercAssist Announces First Patient Enrolled in AVANXA Clinical Feasibility Study using the eVAD™ System for Biventricular Mechanical Circulatory Support
SANTA CLARA, Calif., August 13, 2026 – PercAssist, Inc., a medical device company developing innovative technology for extravascular Biventricular Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced the first patient enrollment for the AVANXA Feasibility Study was successfully conducted in São Paulo, Brazil.
-
PercAssist eVAD™ System Nominated for Jon DeHaan Foundation Innovation Award, Featured in Multiple Sessions at EuroPCR 2026
The PercAssist eVAD™ System Technology was selected as one of the top three innovations from 80 applicants; PV Loop study results presented by investigators from Duke University Medical Center, North Carolina and Erasmus University, Rotterdam / Ziekenhuis Oost Limburg, Belgium , demonstrate biventricular hemodynamic support in cardiogenic shock.
-
Dr. Albert Chin Featured on Innovators’ Journey to Discuss Medical Innovations
Dr. Albert Chin joined USA Today - Innovators’ Journey Host, Nick Franck, to discuss his work on advancing minimally invasive approaches for cardiovascular procedures, including the PercAssist eVAD(TM) System.
-
PercAssist's PSCA System - Intrapericardial Mechanical Circulatory Support (MCS) System for Cardiogenic Shock Presented at the TCT24
PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced that new data was presented at two sessions at the Transcatheter Cardiovascular Therapeutics (TCT24) Conference in Washington, DC, Oct. 27-30, 2024.
-
PercAssist Announces Multiple Patients Treated In the EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure
PercAssist, Inc. announces additional successful in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.
-
PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure
PercAssist, Inc. announces the successful first in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.
-
Innovative Heart Failure Treatment to be Highlighted at the American College of Cardiology
PercAssist to present cutting-edge heart failure technology at major cardiology annual meeting.
-
PercAssist one of ten finalists at the ADA 2022 Silicon Valley Leaders Forum HealthTech Showcase
Company's technology showcased at prestigious competition.